Business Wire8d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
The American Journal of Managed Care8d
FDA Approves Ranibizumab Implant in Treatment of DME
The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...
Morningstar8d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
In Pagoda, people with DME who received Susvimo refilled every six months achieved non-inferior improvements ... associated with endophthalmitis, retinal detachment, and iatrogenic traumatic ...
BMJ5d
Vascular flow density in pathological myopia: an optical coherence tomography angiography study
Design A prospective comparative study was conducted from December 2015 to March 2016. Setting Participants were recruited in Beijing Tongren Hospital. Participants A total of 131 eyes were enrolled, ...
BMJ28d
Observational study of clinical characteristics of dome-shaped macula in Chinese Han with high myopia at Zhongshan Ophthalmic Centre
However, the proportions of extrafoveal schisis (39.66% vs 5.37%), foveal serous retinal detachment (SRD ... Moreover, the ratio of inferior and temporal CT were significantly elevated in the DSM ...
Medscape7d
Management of Primary Rhegmatogenous Retinal Detachment
The two most important factors in the development of rhegmatogenous retinal detachment are retinal breaks and vitreous traction. The two goals of retinal reattachment surgery are to seal all ...
Medscape13d
Retinal Detachment Surgery
He found that the extent of retinal detachment, the number of breaks and the lens status affects the rate of attachment. In a subgroup where less than 25% of the retina is detached with a single ...
Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment
Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...
Forbes24d
From Great Resignation To Great Detachment: 4 Actions Leaders Must Take
Gallup characterizes this trend as the "Great Detachment." While employees may still be physically present, many are psychologically distant. This disengagement can often be subtle, requiring ...